跳至主要内容
临床试验/JPRN-UMIN000021960
JPRN-UMIN000021960招募中未知

Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists. - Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.

Yokohama City University hospital0 个研究点目标入组 20 人开始时间: 2016年4月19日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients corresponding to any of the following are inapplicable in the both GLP-1 receptor agonists group and control group. 1)Patients who ingest the DPP-4 inhibitors. 2)Patients with severe complications (liver disease, mental disorder, or cancer). 3)Patients with severe ketosis or diabetic coma. 4)Patients with severe infections, perioperative status, or severe trauma. 5)Patients whose baseline eGFR were <29 ml/min/1.73m^2. 6)Pregnancy or lactation in women. 7)Patients who are judged by an investigator to be inappropriate for this study for any other reason.

研究者

相似试验